PICO Portalanswers from OpenAlex

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.

PaperCitations, authors & open-access status

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is a paper indexed in PICO Portal from OpenAlex.

How many citations does Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. have?

PICO Portalcitation count

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has 20 citations in the OpenAlex counts PICO Portal stores.

When was Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. published?

PICO Portalyear

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has 2020 year in the PICO Portal index.

Open the OpenAlex record →

What is the open-access status of Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

PICO Portaloa status

Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. has green oa status in the PICO Portal index.

Open the OpenAlex record →

What is the PMID of Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

PICO Portalpmid

The PMID for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is on the source record.

Open the PMID →

What is the OpenAlex record for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling.?

PICO Portalopenalex

The OpenAlex for Acquired rare recurrent EGFR mutations as mechanisms of resistance to Osimertinib in lung cancer and in silico structural modelling. is on the source record.

Open the OpenAlex →

Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.

How many citations does Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling. have?

When was Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling. published?

What is the open-access status of Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

What is the PMID of Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

What is the OpenAlex record for Acquired rare recurrent <i>EGFR</i> mutations as mechanisms of resistance to Osimertinib in lung cancer and <i>in silico</i> structural modelling.?

Related on PICO Portal